FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL										
OMP Number:	3235-0287									
OMB Number:										
Estimated average burden										
hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).	STATEMEN	IT OF CHANGES IN BENEFICIAL OWN	IEF
	Filed	pursuant to Section 16(a) of the Securities Exchange Act of 1930 or Section 30(h) of the Investment Company Act of 1940	4
1. Name and Address of Reporting Person* GAROFALO ELIZABETH A.		2. Issuer Name and Ticker or Trading Symbol Xenon Pharmaceuticals Inc. [XENE]	5 (0

1. Name and Address of Reporting Person* GAROFALO ELIZABETH A.					2. Issuer Name and Ticker or Trading Symbol Xenon Pharmaceuticals Inc. [XENE]									ck all applic	tionship of Reportin all applicable) Director		on(s) to Iss 10% Ov			
(Last) 200 - 365	(F 50 GILMOI	,	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 06/03/2021										Officer below)	(give title		Other (s below)	specify	
(Street) BURNABY A1 V5G 4W8 (City) (State) (Zip) Table I - Non-Deriva					If Amendment, Date of Original Filed (Month/Day/Year) tive Securities Acquired, Disposed of, or Benefice							Line) X	Form fi Form fi Person	vidual or Joint/Group Filing (Check Applicate Form filed by One Reporting Person Form filed by More than One Reporting Person Owned			n	le		
Da			2. Transa Date (Month/D	Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year		Transaction Code (Instr.				4 and Securi		s ally ollowing	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)			
								Code	v	Amount	(A) or (D)		ice	Transact (Instr. 3 a	tion(s)			(
		-	Table II - I						uired, D , option						Owned					_
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution I if any (Month/Day	Date, Ti	ransaction ode (Instr.				6. Date Exercisable Expiration Date (Month/Day/Year)		•	7. Title and Am of Securities Underlying Derivative Secu (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	Owners Form: Direct (l or Indir (l) (Instr	Ownership	Beneficia Ownershi (Instr. 4)	t
				c	ode	v	(A)	(D)	Date Exercisab		Expiration Date	Title	Amo or Num of Shar	ber						
Stock Option (Right to	\$18.56	06/03/2021			A		20,000		(1)	0	06/02/2031	Common	20,0	000	\$0.00	20,000)	D		

Explanation of Responses:

1. One-third of the total shares subject to the Option shall vest on the one year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the two year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the three year anniversary of the grant date.

Remarks:

Buy)

/s/ Cassandra Robinson, Attorney-in-fact

06/03/2021

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.